BEIJING, Oct. 28, 2025 -- Beijing Tsingke Biotech Co., Ltd., a pioneer in molecular manufacturing, showcased its next-generation integrated platforms at the 2025 Festival of Biologics in Basel. Over 2,000 biotech experts from 50 countries attended, witnessing Tsingke's AI-driven solutions for gene and RNA design, antibody discovery, and scalable GMP-grade biologics production, highlighting the company's role in bridging laboratory research with industrial-scale manufacturing. Industry Trends Highlighted: Early-stage developability: process validation begins during discovery
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Oct. 28, 2025 -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology and oncology, today announced the launch of its first fully human Generative AI HCAb (Heavy Chain-Only Antibody) Model powered by its Hu-mAtrIx™ AI platform, built upon the Harbour Mice® platform. This platform establishes a closed-loop process integrating AI design, intelligent screening, and wet-lab validation. The announcement was made at
LAS VEGAS, Oct. 28, 2025 -- TCI Biotech is staking its claim as the "Liquid Expert" of the wellness industry, a title it aims to cement at SupplySide Global 2025. Its core philosophy is that in a crowded wellness landscape, clinical validation and technological superiority, not just marketing, are what ultimately empower brands to succeed. At Booth #5636, the company presents a portfolio of over 40 turnkey products, ranging from metabolic and weight management blends to longevity formulations, offering brands a streamlined pathway to tap into the rapidly expanding liquid supplement
In Partnership with the International League of Dermatological Societies (ILDS) and the International Society of Dermatology (ISD), CeraVe Mobilizes 9 Countries to Expand Access to Dermatological Care Worldwide NEW YORK, Oct. 28, 2025 -- To address the global skin health crisis that leaves billions without access to a dermatologist, CeraVe, the #1 dermatologist-recommended skincare brand in the U.S.*, reached over 3,900 patients around the globe through World Skin Health Day initiatives this summer. World Skin Health Day is led by the International League of Derm
국제피부과학회연맹 및 국제피부과학회와 협력해 9개국을 중심으로 전 세계 피부과 진료 접근성 확대 추진 뉴욕, 2025년 10월 28일 -- 미국 피부과 전문의 추천 1위 스킨케어 브랜드*인 세라비(CeraVe)가 수십억명의 사람들이 피부과 전문의의 진료를 받지 못하는 글로벌 피부건강 위기에 대응하기 위한 일환으로 올여름 세계 피부건강의 날(World Skin Health Day) 캠페인을 통해 전 세계 3900명 이상의 환자를 지원했다. 세계 피부건강의 날은 국제피부과학회연맹(ILDS)과 국제피부과학회(ISD)가 공동으로 주관하는 행사로 피부건강의 중요성에 대한 교육을 제공하고 전 세계 피부건강 개선에 기여하는 토론과 행동을 장려하기 위한 목적으로 매년 7월 8일에 열린다. 이 행사에 2년 연속 공식 기업 파트너로 참여한 세라비는 ILDS 및 ISD와 손잡고 2024년의 성과를 바탕으로 9개국에서 캠페인을 진행하며 전 세계적으로 피부건강 인식 제고 활동을 펼쳤다. 피부건강 위기에 대한 글로벌 인식 제고전 세계 인구의 3분의 1이 피부 질환으로 고통받고 있지만, 일부 국가에서는 인구 백만명당
Prestigious Nobel Prize–winning institution confirms adoption of miLab™ following clinical evaluation "A milestone signaling broader adoption in advanced global healthcare markets" YONGIN, South Korea, Oct. 28, 2025 -- Noul Co., Ltd.(CEO David Lim), an AI-driven blood and cancer diagnostics company, announced the supply of its AI-based malaria diagnostic solution miLab™ MAL to Charité – Universitätsmedizin Berlin, Germany's largest and most prestigious university hospital. Founded over 300 years ago, Charité is ranked No.
State-of-the-art facility expands company's global research and development capabilities THE WOODLANDS, Texas, Oct. 28, 2025 -- SI Group, a leading global developer and manufacturer of performance additives, process solutions, and chemical intermediates, announced the official opening of its European Innovation Centre (EIC) in Four Ashes, United Kingdom. This milestone marks an important expansion of SI Group's global innovation network, strengthening R&D and application development to better serve customers worldwide. The new state-of-the-art facility is equipped wi
HONG KONG, Oct. 28, 2025 -- Sisram Medical Ltd (the "Company" or "Sisram", 1696.HK; together with its subsidiaries collectively referred to as the "Group"), a global consumer wellness group offering Energy-Based Devices (EBD), injectables, and other complementary solutions, today announced its business update for the third quarter of 2025, highlighting solid revenue growth and accelerated momentum across core product segments and key markets. In the third quarter of 2025, the Company achieved double-digit revenue growth compared to the same period last yea
[ 메디채널 김갑성 기자 ] Innovative Achievements Continue to Come to Fruition, Revenue from Innovative Drugs Exceeding RMB6,700 Million in The First Three Quarters of 2025 SHANGHAI, Oct. 28, 2025 -- On October 28, 2025, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma" or "the Group"; SSE: 600196, HKEX: 02196), a leading innovation-driven global healthcare company, announced its financial results for the first three quarters of 2025. In the first three quarters of 2025, Fosun Pharma achieved operating revenue of RMB29,393 million, net profit attributable to s
[ 메디채널 김갑성 기자 ] AESMED to Focus on Promoting the 1111 Hair Care Day Campaign SEOUL, South Korea, Oct. 28, 2025 -- AESMED Co., Ltd., a leading hair loss treatment company in South Korea, announced its participation in Cosmoprof Asia Hong Kong 2025, the largest B2B international beauty trade fair in Asia, to be held from November 12–14, 2025, at the Hong Kong Convention & Exhibition Centre. Cosmoprof Asia brings together global beauty leaders to present the latest technologies, product innovations, and solutions, serving as a key platform shaping the beauty industry worldwide.